Indicators of antioxidant defense, oxidant system and systemic inflammatory response in patients with chronic systolic heart failure, depending on the main clinical and instrumental characteristics

July 5, 2018
660
Resume

Objective — to study the activity of oxidative stress, antioxidant enzymes and immune response in patients with systolic chronic heart failure (CHF), depending on their basic clinical characteristics. Materials and me­thods. 149 patients with systolic CHF due to ischemic heart disease and/or arterial hypertension, as well as dilatational cardiomyopathy II–IV NYHA classes were examined. The control group consisted of 20 practically healthy persons of comparable age. Results. When comparing patients with CHF and healthy controls almost all of the differences were statistically significant. When comparing groups according to the stage, in patients with CHF IIB–III stage significantly higher level of plasma citrulline, a lower level of reserve capacity of the monocytes and lymphocytes were observed. Comparing groups of median weekly average furosemide doses in patients with ≥280 mg, the levels of uric acid and malondialdehyde were significantly higher, along with a decrease in the level of lymphocytes. When comparing groups according to the degree of left ventricular dilatation in patients with end diastolic size >6.8 cm a significant decrease in the level of superoxide dismutase and increase in the level of citrulline plasma were found. In group of patients with atrial fibrillation, diene conjugates, malondialdehyde and products of free radical oxidation of proteins were significantly higher. Conclusions. Patients with CHF and left ventricular ejection fraction <45% are characterized by lower activity of antioxidant enzymes, higher levels of free radical oxidation of lipids and proteins and uric acid. In patients with CHF, tumor necrosis factor-α, interleukin-6 and plasma citrulline levels are significantly higher, along with lower levels of blood lymphocytes.

L.G. Voronkov, N.G. Lipkan, T.I. Gavrylenko, L.S. Mkhitaryan

Key words: chronic heart failure, oxidative stress, immune activation, citrulline.

Published: 05.07.2018

References:

  • Bershova T.V., Monaenkova S.V., Gasanov A.G. (2009) Patogeneticheskoe znachenie apoptoza kardiomiotsitov pri serdechnoy nedostatochnosti. Pediatriya, 88(5): 147–154.
  • Bulaeva N.I., Goluhova O.Z. (2013) Endotelialnaya disfunktsiya i oksidativnyiy stress: rol v razvitii kardiovaskulyarnoy patologii. Kreativnaya kardiologiya, 1: 14–22.
  • Denisov E.N., Kots Ya.I., Bahtiyarov R.Z. (2007) Vliyanie endoteliya i oksida azota na tonus sosudov u bolnyih hronicheskoy serdechnoy nedostatochnostyu. Ter. arhiv, 12: 44–47.
  • Ivanov S.G., Sitnikova M.Yu., Shlyahto E.V. (2006) Rol oksidativnogo stressa v razvitii i progressirovanii hronicheskoy serdechnoy nedostatochnosti: aktualnost i vozmozhnost ego korrektsii. Kardiologiya SNG, 4: 267–270.
  • Rebrova T.Yu., Shipulin V.M., Afanasev S.A. (2012) Rol oksidativnogo stressa v narushenii ritma v rannem posleoperatsionnom periode posle aortokoronarnogo shuntirovaniya i vozmozhnost ih preduprezhdeniya s pomoschyu preparatov askorbinovoy kislotyi. Kardiologiya, 52(7): 73–76.
  • Sukmanova I.A., Yahontov D.A. (2009) Znachenie oksidativnogo stressa i disfunktsii endoteliya pri diastolicheskoy HSN u patsientov raznyih vozrastnyih grupp. kardiol. zhurn., 4: 22–26.
  • Amir O., Paz H., Rogowski O. (2009) Serum oxidative stress level correlates with clinical parameters in chronic systolic heart failure patients. Clin. Cardiol., 32: 199–203.
  • Bahri S., Zerrouk N., Aussel C. (2013) Citrulline: from metabolism to therapeutic use. Nutrition, 29(3): 479–484.
  • Bauersachs J., Schafer A. (2004) Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches. Cur. Vasc. Pharmacol., 2: 115–124.
  • Bui A.L., Horwich T.B., Fonarow G.C. (2011) Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol., 8(1): 30–41.
  • Clarke P.G. (2002) Apoptosis: From morphological types of cell death to interacting pathways. Trends Pharmacol. Sci., 23: 308–310.
  • de Meirelles L.R., Resende Ade C., Matsuura C. et al. (2011) Platelet activation, oxidative stress and overexpression of inducible nitric oxide synthase in moderate heart failure. Clin. Exp. Pharmacol. Physiol., 38(10): 705–710.
  • Doehner W., Springer I., Anker S. (2008) Uric acid in chronic heart failure-current pathophysiological concepts. Eur. J. Heart Failure, 10: 1269–1271.
  • Finkel T. (2003) Oxidant signals and oxidative stress. Curr. Opin. Cell Biol., 15: 247–254.
  • Giordano F.J. (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest., 115: 500–508.
  • Hartupee J., Mann D.L. (2013) Positioning of inflammatory biomarkers in the heart failure landscape. J. Cardiovasc. Transl. Res., 6: 485–492.
  • Каn Н., Finkel M.S. (2001) Interactions between cytokines and neurohormonal systems in failing heart. Heart Fail. Rev., 6(2): 119–127.
  • Karabacak M., Dogan A., Tayyar S. (2014) Oxidative stress status increase in patients with nonischemic heart failure. Med. Princ. Pract., 23: 532–537.
  • Kotur-Stevuljevic J., Memon L., Stefanovic A. et al. (2007) Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin. Biochem., 40: 181–187.
  • Lloyd-Jones D., Adams R.J., Brown T.M. (2010) Executive Summary: Heart Disease and Stroke Statistics 2010 Update: A report from the American Heart Association. Circulation, 121(7): 948–954.
  • Nishiyama Y., Ikeda H., Haramaki N. (1998) Oxidative stress is related to exercise intolerance in patients with heart failure. Am. Heart J., 135(1): 115–120.
  • Ruggiero C., Cherubini A., Bic A. (2006) Uric acid inflammatory markers. Eur. J. Heart Failure, 27: 1174–1181.
  • Szczurek W., Szyguła-Jurkiewicz B. (2015) Oxidative stress and inflammatory markers — the future of heart failure diagnostics? Kardiochir. Torakochir. Polska, 12(2): 145–149.